참고문헌
- Eekhout E, Wijns W, Meier B, Goy JJ. Indications for coronary stent placement: the European view. Eur Heart J 1999;20:1014-9. https://doi.org/10.1053/euhj.1998.1395
- Faxon DP, Spiro TE, Minor S, et al. Low molecular weight heparin in prevention of restenosis after angioplasty. Results of Enoxaparin Restenosis (ERA) Trial. Circulation 1994;90:908-14. https://doi.org/10.1161/01.CIR.90.2.908
- Hamm CW, Reimers J, Ischinger T, Rupprecht HJ, Berger J, Bleifeld W. A randomized study of coronary angioplasty compared with bypass surgery in patients with symptomatic multivessel coronary disease. Ger-man Angioplasty Bypass Surgery Investigation (GABI). N Engl J Med 1994;331:1037-43. https://doi.org/10.1056/NEJM199410203311601
- Kent KM, Bentivoglio LG, Block PC, et al. Longterm efficacy of percutaneous transluminal coronary angioplasty (PTCA): report from the National Heart, Lung, and Blood Institute PTCA Registry. Am J Cardiol 1984;53:27C-31C. https://doi.org/10.1016/0002-9149(84)90741-0
- Forrester JS, Fishbein M, Helfant R, Fagin J. A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. J Am Coll Cardiol 1991;17:758-69. https://doi.org/10.1016/S0735-1097(10)80196-2
- Austin GE, Ratliff NB, Hollman J, Tabei S, Phillips DF. Intimal proli-feration of smooth muscle cells as an explanation for recurrent coronary artery stenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1985;6:369-75. https://doi.org/10.1016/S0735-1097(85)80174-1
- Bae Y, Jeong MH, Ahn YK, et al. Comparison of porcine coronary st-ent restenosis between MAC (Maximal Arterial Re-Creation) stent and Palmaz-Schatz stent. Korean Circ J 1998;28:89-96.
- Giraldo AA, Esposo OM, Meis JM. Intimal hyperplasia as a cause of restenosis after percutaneous transluminal coronary angioplasty. Arch Pathol Lab Med 1985;109:173-5.
- Ahn YK, Jeong MH, Kim JW, et al. Preventive effects of the heparincoated stent on restenosis in the porcine model. Catheter Cardiovasc Interv 1999;48:324-30. https://doi.org/10.1002/(SICI)1522-726X(199911)48:3<324::AID-CCD20>3.0.CO;2-K
- Hong YJ, Jeong MH, Lim SY, et al. Elevated preprocedural high-sensitivity C-reactive protein levels are associated with neointimal hyperplasia and restenosis development after successful coronary artery st-enting. Circ J 2005;69:1477-83. https://doi.org/10.1253/circj.69.1477
- The CAPTURE Investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory angina. Lancet 1997;349:1429-35. https://doi.org/10.1016/S0140-6736(96)10452-9
- The EPILOG Investigators. Platelet glycoprotein IIb / IIIa blockade and low-dose heparin during percutaneous coronary revascularisation. N Engl J Med 1997;336:1689-96. https://doi.org/10.1056/NEJM199706123362401
- Lefkovits J, Ivanhoe RJ, Califf RM, et al. Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous tr-ansluminal coronary angioplasty for acute myocardial infarction. Am J Cardiol 1996;77:1045-51. https://doi.org/10.1016/S0002-9149(96)00128-2
- Topol EJ, Ferguson JJ, Weisman HF, et al. Long term protection from myocardial ischaemic events in a randomised trial of brief integrin beta3 blockade with percutaneous coronary intervention. JAMA 1997;278:479-84. https://doi.org/10.1001/jama.1997.03550060055036
- Packer L, Witt EH, Tritschler HJ. Alpha-lipoic acid as a biological an-tioxidant. Free Radic Biol Med 1995;19:227-50. https://doi.org/10.1016/0891-5849(95)00017-R
- Packer L, Roy S, Sen CK. Alpha-lipoic acid: a metabolic antioxidant and potential redox modulator of transcription. Adv Pharmacol 1997;38:79-101.
- Song SJ, Kim KS, Park YJ, Jeong MH, Ko YM, Cho DL. Preparation of a dual-drug-eluting stent by grafting of ALA with abciximab on a bare metal stent. J Mater Chem 2009;19:8135-41. https://doi.org/10.1039/b910351a
- Schwartz RS, Huber KC, Murphy JG, et al. Restenosis and the proportional neointimal response to coronary artery injury: results in a por-cine model. J Am Coll Cardiol 1992;19:267-74. https://doi.org/10.1016/0735-1097(92)90476-4
- Schwartz RS, Edelman E, Virmani R, et al. Drug-eluting stents in pre-clinical studies: updated consensus recommendations for preclinical evaluation. Circ Cardiovasc Interv 2008;1:143-53. https://doi.org/10.1161/CIRCINTERVENTIONS.108.789974
- Kolodgie FD, John M, Khurana C, et al. Sustained reduction of in-stent neointimal growth with the use of a novel systemic nanoparticle paclitaxel. Circulation 2002;106:1195-8. https://doi.org/10.1161/01.CIR.0000032141.31476.15
- Lincoff AM. Potent complementary clinical benefit of abciximab and stenting during percutaneous coronary revascularization in patients with diabetes mellitus: results of the EPISTENT trial. Am Heart J 2000;139:S46-52. https://doi.org/10.1067/mhj.2000.103743
- Kang KT, Jeong MH, Kim NH, et al. The inhibitory effect of platelet glycoprotein IIb/IIIa receptor blocker-coated stent on porcine coronary stent restenosis. Korean J Med 2001;60:314-23.
- Park OY, Jeong MH, Kim JH, et al. The inhibitory effects of platelet glycoprotein IIb/IIIa receptor blocker-coated stent on neointima formation and inflammatory response in porcine coronary stent restenosis. Korean Circ J 2003;33:439-45.
- Hong YJ, Jeong MH, Kim W, et al. The effects of abciximab (Reopro(r))-coated stents on extracellular matrix synthesis and apoptosis. Korean Circ J 2005;35:290-301.
- Hong YJ, Jeong MH, Kim W, et al. Effect of abciximab-coated stent on in-stent intimal hyperplasia in human coronary arteries. Am J Cardiol 2004;94:1050-4. https://doi.org/10.1016/j.amjcard.2004.06.066
- Kim W, Jeong MH, Kim KH, et al. The clinical results of a platelet glycoprotein IIb/IIIa receptor blocker (abciximab: Reo-Pro)-coated stent in acute myocardial infarction. J Am Coll Cardiol 2006;47:933-8. https://doi.org/10.1016/j.jacc.2005.10.054
- Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care 1999;22:1296-301. https://doi.org/10.2337/diacare.22.8.1296
- Sung MJ, Kim W, Ahn SY, et al. Protective effect of alpha-lipoic acid in lipopolysaccharide-induced endothelial fractalkine expression. Circ Res 2005;97:880-90. https://doi.org/10.1161/01.RES.0000186522.89544.4D
- Lim SY, Bae EH, Jeong MH, et al. The effect of alpha lipoic acid in a porcine in-stent restenosis model. J Cardiol 2009;54:375-85. https://doi.org/10.1016/j.jjcc.2009.06.005
- Park OY, Jeong MH, Kim JH, et al. The role of extracellular matrix within the neointima in a porcine coronary stent restenosis model. Korean Circ J 2003;33:121-9.
피인용 문헌
- Effect of stents coated with a combination of sirolimus and alpha-lipoic acid in a porcine coronary restenosis model vol.27, pp.4, 2011, https://doi.org/10.1007/s10856-015-5622-0
- Optimal Coating Method for a Dual-Layer Stent with Sirolimus and Alpha-Lipoic Acid in a Porcine Coronary Restenosis Model vol.24, pp.8, 2011, https://doi.org/10.1007/s13233-016-4082-9
- Long-term preclinical evaluation of bioabsorbable polymer-coated drug-eluting stent in a porcine model vol.25, pp.7, 2011, https://doi.org/10.1007/s13233-017-5067-z
- Poly-l-lactide Polymer-Based Triple Drug-Eluting Stent with Abciximab, Alpha-Lipoic Acid and Sirolimus in Porcine Coronary Restenosis Model vol.28, pp.1, 2011, https://doi.org/10.1007/s13233-020-8004-5